Saturday, December 19, 2020 7:45:09 PM
VuBru,
While I can accept the fact that they may hold TLD till peer review will occur practically simultaneously, I can't say that I'm certain that will be the case. There are a number of major brokerage conferences early in the New Year beginning with the J.P. Morgan Healthcare Conference. If TLD were announced, I believe there is a good chance that they'd receive invitations to those conferences.
WRT upgrading to the Nasdaq or other major exchange, if results are what we believe them to be, TLD alone should see us at the $4 level or higher prior to further information from a peer reviewed article or presentation. I suspect that we'll have some issues due to not issuing financials on time, but it's possible that so much interest may exist in the company after TLD is issued that a major exchange might make an exception to their rules.
I'm not saying this would happen, if I remember correctly we've been late on the last two quarterlies. If the SEC has accepted the reasoning behind it, perhaps it's not as big a problem as I believe it could be, but I would expect the major exchanges would want at least a couple financials to be issued on time. Frankly, I believe that Institutions will invest regardless of the exchange that we're on, though some may be playing games in doing so.
What do I mean by playing games. With a MM's cooperation they can purchase shares beginning the first day of a quarter, then sell them back to the MM on the very last day of the quarter and nothing needs to be reported. They can repeat this quarter after quarter until such time as the stock meets the qualifications for that specific Institution. If the Nasdaq or NYSE were a requirement, when the stock listed on the exchange, they'd maintain ownership over the quarter, and it would be reported.
I don't know that you'd have a chance at an invitation to J.P. Morgan with news after the first of the year, but I suspect that TLD anytime before the first would at least create the possibility. As I remember it, their are at least a few others that occur early in the year. It's my belief that TLD will move us to a range between $5 and $10 and if I'm right about that, we could make presentations at several of these conferences. As they're investors, not scientific conferences, I believe that LP would be the primary presenter.
It's up to the company, we know they have the data, if they wished they could have a TLD statement out on Monday, it's all about their strategy for unveiling information. I believe the TLD could provide plenty of information that's worthy of discussion with investors and Institutions, but of course the details will be peer reviewed before they're discussed.
Remember, a potential partner or buyer would have full access to everything under confidentiality agreement. Nothing matters wrt either exchange or peer review to a potential partner or purchaser, all that matters is what they see in the trial.
Gary
While I can accept the fact that they may hold TLD till peer review will occur practically simultaneously, I can't say that I'm certain that will be the case. There are a number of major brokerage conferences early in the New Year beginning with the J.P. Morgan Healthcare Conference. If TLD were announced, I believe there is a good chance that they'd receive invitations to those conferences.
WRT upgrading to the Nasdaq or other major exchange, if results are what we believe them to be, TLD alone should see us at the $4 level or higher prior to further information from a peer reviewed article or presentation. I suspect that we'll have some issues due to not issuing financials on time, but it's possible that so much interest may exist in the company after TLD is issued that a major exchange might make an exception to their rules.
I'm not saying this would happen, if I remember correctly we've been late on the last two quarterlies. If the SEC has accepted the reasoning behind it, perhaps it's not as big a problem as I believe it could be, but I would expect the major exchanges would want at least a couple financials to be issued on time. Frankly, I believe that Institutions will invest regardless of the exchange that we're on, though some may be playing games in doing so.
What do I mean by playing games. With a MM's cooperation they can purchase shares beginning the first day of a quarter, then sell them back to the MM on the very last day of the quarter and nothing needs to be reported. They can repeat this quarter after quarter until such time as the stock meets the qualifications for that specific Institution. If the Nasdaq or NYSE were a requirement, when the stock listed on the exchange, they'd maintain ownership over the quarter, and it would be reported.
I don't know that you'd have a chance at an invitation to J.P. Morgan with news after the first of the year, but I suspect that TLD anytime before the first would at least create the possibility. As I remember it, their are at least a few others that occur early in the year. It's my belief that TLD will move us to a range between $5 and $10 and if I'm right about that, we could make presentations at several of these conferences. As they're investors, not scientific conferences, I believe that LP would be the primary presenter.
It's up to the company, we know they have the data, if they wished they could have a TLD statement out on Monday, it's all about their strategy for unveiling information. I believe the TLD could provide plenty of information that's worthy of discussion with investors and Institutions, but of course the details will be peer reviewed before they're discussed.
Remember, a potential partner or buyer would have full access to everything under confidentiality agreement. Nothing matters wrt either exchange or peer review to a potential partner or purchaser, all that matters is what they see in the trial.
Gary
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
